Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Publication year range
1.
Int J Mol Sci ; 25(8)2024 Apr 20.
Article in English | MEDLINE | ID: mdl-38674102

ABSTRACT

Mesenchymal stem cells (MSCs) are an integral part of the tumor microenvironment (TME); however, their role is somewhat controversial: conflicting reports suggest that, depending on the stage of tumor development, MSCs can either support or suppress tumor growth and spread. Additionally, the influence of MSCs on drug resistance is also ambiguous. Previously, we showed that, despite MSCs proliferating significantly more slowly than cancer cells, there are chemotherapeutic drugs which proved to be similarly toxic to both cell types. Here we established 2D co-cultures and 3D co-culture spheroids from different ratios of GFP-expressing, adipose tissue-derived MSCs and A431 epidermoid carcinoma cells tagged with mCherry to investigate the effect of MSCs on cancer cell growth, survival, and drug sensitivity. We examined the cytokine secretion profile of mono- and co-cultures, explored the inner structure of the spheroids, applied MSC-(nutlin-3) and cancer cell-targeting (cisplatin) treatments separately, monitored the response with live-cell imaging and identified a new, double-fluorescent cell type emerging from these cultures. In 2D co-cultures, no effect on proliferation or drug sensitivity was observed, regardless of the changes in cytokine secretion induced by the co-culture. Conversely, 3D spheroids developed a unique internal structure consisting of MSCs, which significantly improved cancer cell survival and resilience to treatment, suggesting that physical proximity and cell-cell connections are required for MSCs to considerably affect nearby cancer cells. Our results shed light on MSC-cancer cell interactions and could help design new, better treatment options for tumors.


Subject(s)
Coculture Techniques , Mesenchymal Stem Cells , Spheroids, Cellular , Mesenchymal Stem Cells/metabolism , Mesenchymal Stem Cells/drug effects , Mesenchymal Stem Cells/cytology , Humans , Spheroids, Cellular/drug effects , Cell Line, Tumor , Tumor Microenvironment , Cell Proliferation/drug effects , Antineoplastic Agents/pharmacology , Drug Resistance, Neoplasm , Cell Survival/drug effects , Cisplatin/pharmacology , Drug Tolerance , Cytokines/metabolism
2.
Cells ; 11(19)2022 09 20.
Article in English | MEDLINE | ID: mdl-36230904

ABSTRACT

Mesenchymal stem cells (MSCs) or fibroblasts are one of the most abundant cell types in the tumor microenvironment (TME) exerting various anti- and pro-apoptotic effects during tumorigenesis, invasion, and drug treatment. Despite the recently discovered importance of MSCs in tumor progression and therapy, the response of these cells to chemotherapeutics compared to cancer cells is rarely investigated. A widely accepted view is that these naive MSCs have higher drug tolerance than cancer cells due to a significantly lower proliferation rate. Here, we examine the differences and similarities in the sensitivity of MSCs and cancer cells to nine diverse chemotherapy agents and show that, although MSCs have a slower cell cycle, these cells are still sensitive to various drugs. Surprisingly, MSCs showed similar sensitivity to a panel of compounds, however, suffered fewer DNA double-stranded breaks, did not enter into a senescent state, and was virtually incapable of apoptosis. Our results suggest that MSCs and cancer cells have different cell fates after drug treatment, and this could influence therapy outcome. These findings could help design drug combinations targeting both MSCs and cancer cells in the TME.


Subject(s)
Antineoplastic Agents , Mesenchymal Stem Cells , Antineoplastic Agents/metabolism , Antineoplastic Agents/pharmacology , Apoptosis , Carcinogenesis/pathology , DNA/metabolism , Humans , Mesenchymal Stem Cells/metabolism , Tumor Microenvironment
3.
Magy Onkol ; 65(2): 176-187, 2021 Jun 03.
Article in Hungarian | MEDLINE | ID: mdl-34081765

ABSTRACT

There are about 14 million new cancer cases and 8 million deaths every year. Every second man and one in every three women will get cancer during their lifetimes. Following decades of steady increase, death rates have stabilized due to increased awareness and prevention, early detection, and the emergence of more effective therapy. Yet despite all the advances cancer remains a major killer. Despite improved therapies, nearly all current treatments face the same problem: for many patients, they ultimately stop working. Therapy resistance is the ultimate challenge facing cancer researchers and patients today. In this review we present an overview of the most important resistance mechanisms, discussing progress in therapies designed to prevent or overcome anticancer therapy resistance. Finally, we present recent findings from our own laboratory on the development of new experimental models and new therapeutic approaches to combat multidrug resistant cancer.


Subject(s)
Neoplasms , Pharmaceutical Preparations , Drug Resistance, Multiple , Drug Resistance, Neoplasm , Female , Humans , Male , Neoplasms/drug therapy
4.
Cells ; 8(4)2019 04 12.
Article in English | MEDLINE | ID: mdl-31013745

ABSTRACT

Recent studies have established that the phenotype of epithelial stem cells residing in the corneal periphery (the limbus) depends on this niche's distinct biomechanical properties. However, the signaling pathways underlying this dependency are still poorly understood. To address this issue, we investigated the effect of substrate stiffness on the migration, proliferation, and molecular phenotype of human limbal epithelial stem cells (LESCs). Specifically, we demonstrated that cells grown on collagen-based substrates with limbus-like compliance showed higher proliferation and stratification and lower migration capabilities, as well as higher levels of pro-proliferative markers Ki67 and ß-Catenin, and LESC markers ΔNp63, ABCG2, and CK15. In contrast, cells on stiffer substrates lost these stem/progenitor cell markers, but instead expressed the key mechanotransduction factor YAP, as well as elevated levels of BMP4, a promotor of cell differentiation known to be negatively regulated by Wnt/ß-Catenin signaling. This data allowed us to propose a new model that integrates the various molecular pathways involved in LESC response to substrate stiffness. This model will potentially be a useful guide to future research on the mechanisms underlying LESC loss following fibrosis-causing injuries.


Subject(s)
Limbus Corneae/cytology , Limbus Corneae/metabolism , Stem Cells/physiology , Adaptor Proteins, Signal Transducing/genetics , Adaptor Proteins, Signal Transducing/metabolism , Aged , Cell Differentiation , Cell Proliferation , Cornea/metabolism , Corneal Diseases/metabolism , Epithelial Cells/cytology , Epithelial Cells/metabolism , Epithelium/metabolism , Epithelium, Corneal/cytology , Female , Humans , Limbus Corneae/physiology , Male , Mechanotransduction, Cellular , Phenotype , Signal Transduction , Tissue Engineering/methods , Tissue Scaffolds/chemistry , Transcription Factors/genetics , Transcription Factors/metabolism , Tumor Suppressor Proteins/genetics , Tumor Suppressor Proteins/metabolism , YAP-Signaling Proteins , beta Catenin/genetics , beta Catenin/metabolism
5.
Cereb Cortex ; 28(6): 2109-2117, 2018 06 01.
Article in English | MEDLINE | ID: mdl-28505229

ABSTRACT

Nogo-A has been well described as a myelin-associated inhibitor of neurite outgrowth and functional neuroregeneration after central nervous system (CNS) injury. Recently, a new role of Nogo-A has been identified as a negative regulator of synaptic plasticity in the uninjured adult CNS. Nogo-A is present in neurons and oligodendrocytes. However, it is yet unclear which of these two pools regulate synaptic plasticity. To address this question we used newly generated mouse lines in which Nogo-A is specifically knocked out in (1) oligodendrocytes (oligoNogo-A KO) or (2) neurons (neuroNogo-A KO). We show that both oligodendrocyte- and neuron-specific Nogo-A KO mice have enhanced dendritic branching and spine densities in layer 2/3 cortical pyramidal neurons. These effects are compartmentalized: neuronal Nogo-A affects proximal dendrites whereas oligodendrocytic Nogo-A affects distal regions. Finally, we used two-photon laser scanning microscopy to measure the spine turnover rate of adult mouse motor cortex layer 5 cells and find that both Nogo-A KO mouse lines show enhanced spine remodeling after 4 days. Our results suggest relevant control functions of glial as well as neuronal Nogo-A for synaptic plasticity and open new possibilities for more selective and targeted plasticity enhancing strategies.


Subject(s)
Dendritic Spines/metabolism , Motor Cortex/metabolism , Neuronal Plasticity/physiology , Nogo Proteins/metabolism , Oligodendroglia/metabolism , Animals , Mice , Mice, Knockout , Neurons/metabolism
6.
Brain Struct Funct ; 221(1): 317-29, 2016 Jan.
Article in English | MEDLINE | ID: mdl-25284126

ABSTRACT

The inhibitory action of Nogo-A on axonal growth has been well described. However, much less is known about the effects that Nogo-A could exert on the plasticity of neuronal circuits under physiological conditions. We investigated the effects of Nogo-A knock-out (KO) on visual function of adult mice using the optokinetic response (OKR) and the monocular deprivation (MD)-induced OKR plasticity and analyzed the anatomical organization of the eye-specific retinal projections. The spatial frequency sensitivity was higher in intact Nogo-A KO than in wild-type (WT) mice. After MD, Nogo-A KO mice reached a significantly higher spatial frequency and contrast sensitivity. Bilateral ablation of the visual cortex did not affect the OKR sensitivity before MD but reduced the MD-induced enhancement of OKR by approximately 50% in Nogo-A KO and WT mice. These results suggest that cortical and subcortical brain structures contribute to the OKR plasticity. The tracing of retinal projections to the dorsal lateral geniculate nucleus (dLGN) revealed that the segregation of eye-specific terminals was decreased in the adult Nogo-A KO dLGN compared with WT mice. Strikingly, MD of the right eye led to additional desegregation of retinal projections in the left dLGN of Nogo-A KO but not in WT mice. In particular, MD promoted ectopic varicosity formation in Nogo-A KO dLGN axons. The present data show that Nogo-A restricts visual experience-driven plasticity of the OKR and plays a role in the segregation and maintenance of retinal projections to the brain.


Subject(s)
Blindness/metabolism , Myelin Proteins/deficiency , Neuronal Plasticity , Nystagmus, Optokinetic , Optic Nerve/metabolism , Retina/metabolism , Vision, Ocular , Visual Cortex/metabolism , Animals , Blindness/genetics , Blindness/physiopathology , Contrast Sensitivity , Disease Models, Animal , Gene Deletion , Genotype , Male , Mice, Inbred C57BL , Mice, Knockout , Myelin Proteins/genetics , Nogo Proteins , Optic Nerve/physiopathology , Phenotype , Photic Stimulation , Retina/physiopathology , Spatial Navigation , Time Factors , Visual Cortex/physiopathology , Visual Cortex/surgery , Visual Pathways/metabolism , Visual Pathways/physiopathology
7.
Stem Cells Dev ; 24(18): 2193-205, 2015 Sep 15.
Article in English | MEDLINE | ID: mdl-26110923

ABSTRACT

Ring1 and Yy1 binding protein (Rybp) has been implicated in transcriptional regulation, apoptotic signaling and as a member of the polycomb repressive complex 1, it has an important function in regulating pluripotency and differentiation of embryonic stem cells (ESCs). Earlier, we had proved that Rybp plays an essential role in mouse embryonic and central nervous system development. This work identifies Rybp, as a critical regulator of heart development. Rybp is readily detectable in the developing mouse heart from day 8.5 of embryonic development. Prominent Rybp expression persists during all embryonic stages, and Rybp marks differentiated cell types of the heart. By utilizing rybp null ESCs in an in vitro cardiac differentiation assay, we found that rybp null ESCs do not form rhythmically beating cardiomyocytes (CMCs). Gene expression profiles revealed a downregulation of cardiac terminal and upregulation of germline-specific markers in the rybp null CMCs. Furthermore, transcriptome analysis uncovered a number of novel candidate target genes regulated by Rybp. Among these are several that are important in cardiac development and contractility such as Plagl1, Isl1, and Tnnt2. Importantly, forced expression of rybp in rybp-deficient ESCs by a lentiviral vector was able to rescue the mutant phenotype. Our data provide evidence for a previously unrecognized function of Rybp in heart development and point out the importance of germ cell lineage gene silencing during somatic differentiation.


Subject(s)
Heart/embryology , Mouse Embryonic Stem Cells/cytology , Myocytes, Cardiac/cytology , Organogenesis/genetics , Repressor Proteins/genetics , Animals , Cell Cycle Proteins/genetics , Cell Differentiation/genetics , Cell Lineage/genetics , Cells, Cultured , Embryonic Development/genetics , Gene Expression Regulation, Developmental , Genes, Tumor Suppressor , LIM-Homeodomain Proteins/genetics , Mice , Myocardium/cytology , Polycomb Repressive Complex 1/metabolism , Transcription Factors/genetics , Troponin T/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...